New York, USA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tetanus Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight Tetanus is a serious bacterial infection caused by Clostridium tetani, which affects the nervous system, leading to muscle stiffness and spasms. With an increased awareness of disease prevention, there is a rising demand for vaccines and boosters among general populations, especially among travelers and those exposed to occupational risks.
DelveInsight’s ' Tetanus Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline tetanus therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the tetanus pipeline domain. Key Takeaways from the Tetanus Pipeline Report DelveInsight’s tetanus pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline tetanus drugs. Key tetanus companies such as G C Pharma, KM Biologics, Trinomab Biotech, Beijing Zhifei Lvzhu Biopharmaceutical Co.
, Ltd, Sinovac, Life Sciences Genrix Biopharmaceuticals, Changchun BCHT Biotechnology Co., and others are evaluating new tetanus drugs to improve the treatment landscape. Promising pipeline tetanus therapies such as GC 3111A, KD-370, TNM 002, Adsorbed diphtheria tetanus acellular pertussis combined vaccine, Tetanus vaccine, GR 2001, CBL 8851, and others are under different phases of tetanus clinical trials.
In October 2024, .
